https://www.macrotrends.net/stocks/charts/BIOVF/swedish-orphan-biovitrum/return-on-tangible-equity
Current and historical return on tangible equity values for Swedish Orphan Biovitrum (BIOVF) over the last 10 years. Return on tangible equity can be defined...
swedish orphan biovitrumreturntangibleequity
https://www.macrotrends.net/stocks/charts/BIOVF/swedish-orphan-biovitrum/pre-tax-profit-margin
Current and historical pre-tax profit margin for Swedish Orphan Biovitrum (BIOVF) from 2019 to 2025. Pre-tax profit margin can be defined as earnings before...
swedish orphan biovitrumtax profitpremargin
https://www.pharmaceutical-technology.com/data-insights/anakinra-swedish-orphan-biovitrum-cytokine-release-syndrome-cytokine-storm-likelihood-of-approval/
Anakinra is under clinical development by Swedish Orphan Biovitrum and currently in Phase II for Cytokine Release Syndrome (Cytokine Storm).
swedish orphan biovitrumcytokine release syndromeanakinra
https://www.pharmaceutical-technology.com/data-insights/loncastuximab-tesirine-swedish-orphan-biovitrum-marginal-zone-b-cell-lymphoma-likelihood-of-approval/
Loncastuximab tesirine is under clinical development by Swedish Orphan Biovitrum and currently in Phase I for Marginal Zone B-cell Lymphoma.
swedish orphan biovitrumloncastuximab tesirinemarginal zone
https://www.macrotrends.net/stocks/charts/BIOVF/swedish-orphan-biovitrum/eps-earnings-per-share-diluted
Swedish Orphan Biovitrum annual and quarterly earnings per share history from 2019 to 2025. Earnings per share can be defined as a company's net earnings or...
swedish orphan biovitrumearnings per shareeps
https://www.pharmaceutical-technology.com/news/deals-this-week-medicines-for-malaria-venture-swedish-orphan-biovitrum-atyr-pharma/
Medicines for Malaria Venture (MMV) has entered a collaboration with Drugs for Neglected Disease initiative (DNDi) to create a pandemic response box.
swedish orphan biovitrumdealsweekmedicinesmalaria